Drugs

Be aware of possibility of acute uveitis after IV zoledronate for osteoporosis
Ocular pain, blurred vision, photosensitivity, hyperemia and other ocular symptoms may begin two to four days after the bisphosphonate infusion.
4 clinically significant drug-drug interactions docs should remember when prescribing
Doctors need to fight the inertia that can result from software programs providing a full list of DDIs—some of which aren't clinically significant.

Health Canada conditionally approves Lynparza for some prostate cancer

Health Canada has conditionally approved Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone.
POP QUIZ: Qulipta for migraine

Can you find the false statement?
Anti-inflammatories linked to reduced depression in spondyloarthritis patients

But tough sorting out how much is related to reducing disease symptoms.
New drug to protect babies and toddlers from RSV gets U.S. FDA approval ahead of cold season

Last year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
Second Alzheimer’s drug in pipeline can slow the disease by a few months but with safety risk

Eli Lilly and Co. is seeking U.S. Food and Drug Administration approval of donanemab. If cleared, it would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease—after the recently approved Leqembi from Japanese drugmaker Eisai.
First over-the-counter birth control pill gets U.S. FDA approval

The manufacturer, Ireland-based Perrigo, won’t start shipping the pill until early next year, and there will be no age restrictions on sales.
Drug news—July 2023

A review of new launches, new indications, new dosage forms and Health Canada advisories.
Health Canada grants conditional approval for Ondexxya to reverse FXa inhibitor anticoagulant effects

Andexanet alfa will be used intravenously to rapidly reverse life-threatening or uncontrolled bleeding due to rivaroxaban or apixaban.

Be aware of possibility of acute uveitis after IV zoledronate for osteoporosis

4 clinically significant drug-drug interactions docs should remember when prescribing

Health Canada conditionally approves Lynparza for some prostate cancer

POP QUIZ: Qulipta for migraine

Anti-inflammatories linked to reduced depression in spondyloarthritis patients

New drug to protect babies and toddlers from RSV gets U.S. FDA approval ahead of cold season

Second Alzheimer’s drug in pipeline can slow the disease by a few months but with safety risk

First over-the-counter birth control pill gets U.S. FDA approval

Drug news—July 2023

Health Canada grants conditional approval for Ondexxya to reverse FXa inhibitor anticoagulant effects